Improvement of tumor-to-blood ratio of radioimmunoconjugates by poly(ethyleneimine)-containing chelating agent
Annals of Nuclear Medicine · 2025
DOI: 10.1007/s12149-024-02003-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Nuclear Medicine, 2025. Verfasst von Kazuma Nakashima und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Ky…. Hauptthemen laut MEDLINE: Chelating Agents, Polyethyleneimine, Immunoconjugates. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: AMED.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
- Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan. ono@pharm.kyoto-u.ac.jp.
Förderung
- AMED
Zitieren
APA
Nakashima, K., Shimohara, H., Watanabe, H., & Ono, M. (2025). Improvement of tumor-to-blood ratio of radioimmunoconjugates by poly(ethyleneimine)-containing chelating agent. Annals of Nuclear Medicine. https://doi.org/10.1007/s12149-024-02003-6
Vancouver
Nakashima K, Shimohara H, Watanabe H, Ono M. Improvement of tumor-to-blood ratio of radioimmunoconjugates by poly(ethyleneimine)-containing chelating agent. Annals of Nuclear Medicine. 2025. doi:10.1007/s12149-024-02003-6
BibTeX
@article{Nakashima2025,
author = {Nakashima, Kazuma and Shimohara, Hiroki and Watanabe, Hiroyuki and Ono, Masahiro},
title = {Improvement of tumor-to-blood ratio of radioimmunoconjugates by poly(ethyleneimine)-containing chelating agent},
journal = {Annals of Nuclear Medicine},
year = {2025},
doi = {10.1007/s12149-024-02003-6}
}
EUVIMED